Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism.

D'Alessio A, Marchetti M, Tartari CJ, Russo L, Cecchini S, Lambregts KWFM, di Mauro D, Falanga A.

Cancer Invest. 2017 Aug 9;35(7):490-499. doi: 10.1080/07357907.2017.1340480. Epub 2017 Jul 10.

PMID:
28692314
2.

Platelet haemostatic properties in β-thalassaemia: the effect of blood transfusion.

Trinchero A, Marchetti M, Giaccherini C, Tartari CJ, Russo L, Falanga A.

Blood Transfus. 2017 Sep;15(5):413-421. doi: 10.2450/2016.0033-16. Epub 2016 Oct 4.

3.

FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor.

Peterlongo P, Catucci I, Colombo M, Caleca L, Mucaki E, Bogliolo M, Marin M, Damiola F, Bernard L, Pensotti V, Volorio S, Dall'Olio V, Meindl A, Bartram C, Sutter C, Surowy H, Sornin V, Dondon MG, Eon-Marchais S, Stoppa-Lyonnet D, Andrieu N, Sinilnikova OM; GENESIS, Mitchell G, James PA, Thompson E; kConFab; SWE-BRCA, Marchetti M, Verzeroli C, Tartari C, Capone GL, Putignano AL, Genuardi M, Medici V, Marchi I, Federico M, Tognazzo S, Matricardi L, Agata S, Dolcetti R, Della Puppa L, Cini G, Gismondi V, Viassolo V, Perfumo C, Mencarelli MA, Baldassarri M, Peissel B, Roversi G, Silvestri V, Rizzolo P, Spina F, Vivanet C, Tibiletti MG, Caligo MA, Gambino G, Tommasi S, Pilato B, Tondini C, Corna C, Bonanni B, Barile M, Osorio A, Benitez J, Balestrino L, Ottini L, Manoukian S, Pierotti MA, Renieri A, Varesco L, Couch FJ, Wang X, Devilee P, Hilbers FS, van Asperen CJ, Viel A, Montagna M, Cortesi L, Diez O, Balmaña J, Hauke J, Schmutzler RK, Papi L, Pujana MA, Lázaro C, Falanga A, Offit K, Vijai J, Campbell I, Burwinkel B, Kvist A, Ehrencrona H, Mazoyer S, Pizzamiglio S, Verderio P, Surralles J, Rogan PK, Radice P.

Hum Mol Genet. 2015 Sep 15;24(18):5345-55. doi: 10.1093/hmg/ddv251. Epub 2015 Jun 30.

4.

Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia.

Marchetti M, Tartari CJ, Russo L, Panova-Noeva M, Leuzzi A, Rambaldi A, Finazzi G, Woodhams B, Falanga A.

Am J Hematol. 2014 Jan;89(1):68-73. doi: 10.1002/ajh.23590. Epub 2013 Nov 20.

5.

ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.

Panova-Noeva M, Marchetti M, Russo L, Tartari CJ, Leuzzi A, Finazzi G, Rambaldi A, ten Cate H, Falanga A.

Thromb Res. 2013 Jul;132(1):88-93. doi: 10.1016/j.thromres.2013.05.003. Epub 2013 Jun 2.

PMID:
23735588
6.

Microparticles in tumor progression.

Falanga A, Tartari CJ, Marchetti M.

Thromb Res. 2012 Apr;129 Suppl 1:S132-6. doi: 10.1016/S0049-3848(12)70033-6.

PMID:
22682124
7.

Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia.

Falanga A, Russo L, Tartari CJ.

Mediterr J Hematol Infect Dis. 2011;3(1):e2011068. doi: 10.4084/MJHID.2011.068. Epub 2011 Dec 21.

8.

Dissection of the RET/β-catenin interaction in the TPC1 thyroid cancer cell line.

Tartari CJ, Donadoni C, Manieri E, Mologni L, Mina PD, Villa A, Gambacorti-Passerini C.

Am J Cancer Res. 2011;1(6):716-25. Epub 2011 Jun 1.

9.

The ALK gene, an attractive target for inhibitor development.

Tartari CJ, Scapozza L, Gambacorti-Passerini C.

Curr Top Med Chem. 2011;11(11):1406-19. Review.

PMID:
21513493
10.

Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase.

Tartari CJ, Gunby RH, Coluccia AM, Sottocornola R, Cimbro B, Scapozza L, Donella-Deana A, Pinna LA, Gambacorti-Passerini C.

J Biol Chem. 2008 Feb 15;283(7):3743-50. Epub 2007 Dec 10.

11.

Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy.

Gunby RH, Sala E, Tartari CJ, Puttini M, Gambacorti-Passerini C, Mologni L.

Anticancer Agents Med Chem. 2007 Nov;7(6):594-611. Review.

PMID:
18045055
12.

NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.

Galietta A, Gunby RH, Redaelli S, Stano P, Carniti C, Bachi A, Tucker PW, Tartari CJ, Huang CJ, Colombo E, Pulford K, Puttini M, Piazza RG, Ruchatz H, Villa A, Donella-Deana A, Marin O, Perrotti D, Gambacorti-Passerini C.

Blood. 2007 Oct 1;110(7):2600-9. Epub 2007 May 30.

13.

Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.

Gunby RH, Ahmed S, Sottocornola R, Gasser M, Redaelli S, Mologni L, Tartari CJ, Belloni V, Gambacorti-Passerini C, Scapozza L.

J Med Chem. 2006 Sep 21;49(19):5759-68.

PMID:
16970400
14.

An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase.

Gunby RH, Tartari CJ, Porchia F, Donella-Deana A, Scapozza L, Gambacorti-Passerini C.

Haematologica. 2005 Jul;90(7):988-90.

15.

Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy.

Coluccia AM, Gunby RH, Tartari CJ, Scapozza L, Gambacorti-Passerini C, Passoni L.

Expert Opin Ther Targets. 2005 Jun;9(3):515-32. Review.

PMID:
15948671
16.

Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity.

Donella-Deana A, Marin O, Cesaro L, Gunby RH, Ferrarese A, Coluccia AM, Tartari CJ, Mologni L, Scapozza L, Gambacorti-Passerini C, Pinna LA.

Biochemistry. 2005 Jun 14;44(23):8533-42.

PMID:
15938644

Supplemental Content

Loading ...
Support Center